• Mashup Score: 0
    VJHemOnc – The video journal of hematological oncology - 8 month(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      It’s the first day of #SOHO2023 and we’re already having a wonderful time! Exciting talks in #ALLsm, #MDSsm, #AMLsm & more today – look out for our interviews with speakers on https://t.co/O9p0vDBrzw! @SocietyofHemOnc #LeuSM #LymSM https://t.co/Y0noMhjbcr

  • Mashup Score: 0
    The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space - 8 month(s) ago

    Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses how therapy is evolving for Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL), highlighting the growing role of immunotherapy in this space, and commenting on the importance of measurable residual disease (MRD)-guided therapy in ALL. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Robin Foà of @SapienzaRoma discusses the evolution of therapy in Ph+ and Ph- ALL, highlighting the growing role of immunotherapy & the value of MRD-guided therapy in this disease: 👉 https://t.co/rg55r8vxyC 👈 #EHA2023 #LeuSM #ALLsm #ImmunoOnc

  • Mashup Score: 0
    The impact of thrombosis on outcomes in pediatric ALL - 9 month(s) ago

    Marie-Claude Pelland-Marcotte, MD, PhD, Laval University, Quebec City, Canada, discusses her research into the impact of thrombosis on the outcomes of pediatric patients with acute lymphoblastic leukemia (ALL). Dr Pelland-Marcotte shares that early thrombosis appears to be associated with reduced survival, before highlighting the need for further research. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Want to learn more about the impact of thrombosis on the outcomes of pediatric patients with ALL? Watch our interview with Marie-Claude Pelland-Marcotte of @universitelaval from #ISTH2023: 🎥 https://t.co/ejHkxIk9A4 @isth #HemOnc #LeuSM #ALLsm

  • Mashup Score: 2
    Phase I trial of INA03 in patients with R/R acute leukemia: preliminary results - 9 month(s) ago

    Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, briefly discusses the preliminary results from a Phase I trial evaluating the safety and efficacy of INA03, an anti-CD71 antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute leukemias (AL; NCT03957915). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      At #EHA2023, we caught up with @GarciazSylvain (@paoli_calmettes), who shared some preliminary findings from a Phase I trial evaluating INA03 in patients with R/R acute leukemias 👇: https://t.co/k7Bn8cle9S @EHA_Hematology #LeuSM #HemOnc #AMLsm #ALLsm #ImmunoOnc

  • Mashup Score: 1
    ISTH 2023 | VJHemOnc - 10 month(s) ago

    The 31st Congress of the International Society on Thrombosis and Haemostasis 24–28 June 2023 | Montréal, Canada The 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) is being held in Montréal, Canada, between 24-28 June, 2023. This meeting will bring together leading experts as they…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Another lovely interview at #ISTH2023 w/ Marie-Claude Pelland-Marcotte of @universitelaval on thrombosis during induction chemotherapy in pediatric ALL. Our interviews can be found on https://t.co/t8yVeTkv6f! #LeuSM #ALLsm #HemOnc https://t.co/DzW9k3E0cy

  • Mashup Score: 0
    Ponatinib & blinatumomab for Ph+ ALL - 10 month(s) ago

    A chemotherapy-free regimen with simultaneous ponatinib and blinatumomab was found to have good safety signals and to be efficacious in…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #EHA2023 | @NicholasShortMD of @MDAndersonNews discusses the safety & efficacy of ponatinib & blinatumomab in patients with Ph+ ALL: 🎥 https://t.co/NuAXfVxnSQ @EHA_Hematology #LeuSM #ALLsm #HemOnc #ImmunoOnc

Load More